TW290540B - - Google Patents

Info

Publication number
TW290540B
TW290540B TW083111189A TW83111189A TW290540B TW 290540 B TW290540 B TW 290540B TW 083111189 A TW083111189 A TW 083111189A TW 83111189 A TW83111189 A TW 83111189A TW 290540 B TW290540 B TW 290540B
Authority
TW
Taiwan
Prior art keywords
trisubstituted
piperidinyl
alkylcarboxylates
congeners
carboxylates
Prior art date
Application number
TW083111189A
Other languages
English (en)
Chinese (zh)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of TW290540B publication Critical patent/TW290540B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW083111189A 1993-12-08 1994-12-01 TW290540B (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/164,074 US5434171A (en) 1993-12-08 1993-12-08 Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates

Publications (1)

Publication Number Publication Date
TW290540B true TW290540B (en:Method) 1996-11-11

Family

ID=22592858

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083111189A TW290540B (en:Method) 1993-12-08 1994-12-01

Country Status (30)

Country Link
US (1) US5434171A (en:Method)
EP (3) EP0657428B1 (en:Method)
JP (2) JP3834075B2 (en:Method)
KR (1) KR100356239B1 (en:Method)
CN (2) CN1057294C (en:Method)
AT (1) ATE200279T1 (en:Method)
AU (1) AU681198B2 (en:Method)
BR (1) BR9404842A (en:Method)
CA (1) CA2137221C (en:Method)
CO (1) CO4290427A1 (en:Method)
CZ (1) CZ290559B6 (en:Method)
DE (1) DE69427017T2 (en:Method)
DK (1) DK0657428T3 (en:Method)
ES (1) ES2155844T3 (en:Method)
FI (2) FI106455B (en:Method)
GR (1) GR3036136T3 (en:Method)
HU (1) HUT71489A (en:Method)
IL (1) IL111843A (en:Method)
MY (1) MY121543A (en:Method)
NO (1) NO302884B1 (en:Method)
NZ (1) NZ270039A (en:Method)
PE (1) PE41495A1 (en:Method)
PL (1) PL181734B1 (en:Method)
PT (1) PT657428E (en:Method)
RU (1) RU2145958C1 (en:Method)
SI (1) SI0657428T1 (en:Method)
TW (1) TW290540B (en:Method)
UA (1) UA52577C2 (en:Method)
YU (2) YU49312B (en:Method)
ZA (1) ZA949584B (en:Method)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722497B1 (fr) * 1994-07-13 1996-08-14 Synthelabo Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique
HN1999000149A (es) * 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
JP2004535419A (ja) * 2001-06-05 2004-11-25 ユニバーシティ オブ シカゴ 免疫抑制を処置するためのメチルナルトレキソンの使用
US20030068829A1 (en) * 2001-06-25 2003-04-10 Symyx Technologies, Inc. High throughput crystallographic screening of materials
SI2939696T1 (sl) 2001-10-18 2016-06-30 Nektar Therapeutics Polimerni konjugati opioidnih antagonistov
US6794510B2 (en) * 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
EP2368554B1 (en) 2003-04-08 2014-12-24 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
AU2004229462A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
US20050148630A1 (en) * 2003-12-02 2005-07-07 Carpenter Randall L. Methods of preventing and treating non-opioid induced gastrointestinal dysfunction
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
EA015333B1 (ru) * 2003-12-16 2011-06-30 Нектар Терапьютикс Композиции, содержащие конъюгаты, способы их получения и применение
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050240177A1 (en) * 2004-04-26 2005-10-27 Packaging Service Corporation Of Kentucky Electrosurgical forceps
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
CN100579373C (zh) * 2004-06-04 2010-01-13 阿得罗公司 包含鸦片样物质拮抗剂的组合物
EP1789067B8 (en) * 2004-08-12 2012-08-15 Helsinn Healthcare S.A. Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
EP1906952A4 (en) * 2005-07-01 2010-04-14 Jenrin Discovery MAO-B INHIBITORS USEFUL IN THE TREATMENT OF OBESITY
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
CN100383121C (zh) * 2006-03-07 2008-04-23 天津泰普药品科技发展有限公司 阿韦苄酯化合物及其制备方法和以该化合物制备阿韦莫哌的工艺
CN101426481B (zh) 2006-04-21 2012-12-05 帝斯曼知识产权资产管理有限公司 阿片受体拮抗剂的用途
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
MX2009005455A (es) * 2006-11-22 2009-08-28 Progenics Pharm Inc (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
ES2493590T3 (es) 2007-03-29 2014-09-12 Wyeth Llc Antagonistas de receptores opioides periféricos y usos de los mismos
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
AU2008233129B2 (en) 2007-03-29 2014-03-20 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CN102159250B (zh) 2008-08-11 2014-08-06 尼克塔治疗公司 多臂的聚合烷酸酯偶联物
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN101429154B (zh) * 2008-11-14 2011-01-05 天津泰普药品科技发展有限公司 无水阿维莫泮及其药物组合物
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
US9119848B2 (en) 2009-12-04 2015-09-01 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose
WO2011161646A2 (en) 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
CN103360302B (zh) * 2012-03-29 2015-08-26 北大方正集团有限公司 阿维莫泮的纯化方法
US10314839B2 (en) 2014-10-20 2019-06-11 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
WO2017059459A1 (en) 2015-10-01 2017-04-06 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTIPLE SUBUNITY OPIOID PRODRUGS WITH RESISTANCE TO OVERDOSE AND ABUSE
KR20250093323A (ko) * 2022-10-27 2025-06-24 가부시키가이샤 교토 소야쿠 겐큐쇼 나프탈렌 유도체의 결정

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US5136040A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Preparation of substituted tetrahydropyridines
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
CZ284993B6 (cs) * 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu

Also Published As

Publication number Publication date
JPH07215937A (ja) 1995-08-15
EP1607387A3 (en) 2007-01-03
EP0657428A1 (en) 1995-06-14
NZ270039A (en) 1996-08-27
PL181734B1 (pl) 2001-09-28
CZ299294A3 (en) 1995-10-18
DK0657428T3 (da) 2001-05-07
EP0984004A3 (en) 2003-10-15
YU82304A (sh) 2006-03-03
MY121543A (en) 2006-02-28
CA2137221A1 (en) 1995-06-09
EP0984004A2 (en) 2000-03-08
HUT71489A (en) 1995-11-28
FI945703L (fi) 1995-06-09
CN1057294C (zh) 2000-10-11
IL111843A (en) 2000-02-29
BR9404842A (pt) 1995-08-08
PE41495A1 (es) 1995-11-28
ES2155844T3 (es) 2001-06-01
KR100356239B1 (ko) 2002-12-26
CN1111239A (zh) 1995-11-08
FI106455B (fi) 2001-02-15
HK1013826A1 (en) 1999-09-10
JP3834075B2 (ja) 2006-10-18
ATE200279T1 (de) 2001-04-15
CN1223257A (zh) 1999-07-21
IL111843A0 (en) 1995-03-15
SI0657428T1 (en) 2001-08-31
EP1607387A2 (en) 2005-12-21
FI20000353L (fi) 2000-02-17
YU70294A (sh) 1997-07-31
CO4290427A1 (es) 1996-04-17
AU7917094A (en) 1995-06-15
PT657428E (pt) 2001-07-31
RU94042903A (ru) 1996-10-27
ZA949584B (en) 1996-06-03
FI106860B (fi) 2001-04-30
HU9403466D0 (en) 1995-02-28
EP0657428B1 (en) 2001-04-04
US5434171A (en) 1995-07-18
DE69427017T2 (de) 2001-09-06
GR3036136T3 (en) 2001-09-28
RU2145958C1 (ru) 2000-02-27
CA2137221C (en) 2011-02-22
PL306068A1 (en) 1995-06-12
JP2006070042A (ja) 2006-03-16
NO302884B1 (no) 1998-05-04
AU681198B2 (en) 1997-08-21
NO944644L (no) 1995-06-09
FI945703A0 (fi) 1994-12-02
DE69427017D1 (de) 2001-05-10
KR950017957A (ko) 1995-07-22
YU49312B (sh) 2005-06-10
UA52577C2 (uk) 2003-01-15
CZ290559B6 (cs) 2002-08-14
CN1121387C (zh) 2003-09-17
NO944644D0 (no) 1994-12-02

Similar Documents

Publication Publication Date Title
TW290540B (en:Method)
KR100210761B1 (en) 1,3-oxazin-4-one derivative herbicide containing the same and novel intermediate for producing the same
HUT70178A (en) Process for preparing 2,2-difluoro-ketene-silyl-acetals and alpha, alpha-difluoro-beta-silyloxy-1,3-dioxolane-4-propanoic acid esters
SG44824A1 (en) Process for the hydroformylation of 1,3-butadiene
HUT69063A (en) Process for the preparation of 1,4-disubstituted-5(4h)-tetrazolinones
TW198026B (en:Method)
SG70985A1 (en) Process for producing 1,4-dienes
AU3689193A (en) Method of treating osteoporosis with 1 alpha, 24 (R)-dihydroxy-22 (E)-dehydro-vitamin D3
EP0645194A3 (de) Handbetätigtes Werkzeug.
SG43779A1 (en) Process for producing 1,4-dicyano-2-butene
ZA938576B (en) Process for preparing 1,3-difluorobenzene
AU5538790A (en) Intermediates for the production of 2,4,5-trifluorbenzoyl fluoride
EP0429060A3 (en) Benzothiazepines
IL104477A0 (en) Process for preparing 4,6-dialkoxy-pyrimidines
IL132504A0 (en) Methods for reducing fibrinogen
AU1681895A (en) Process for preparing 4,4-dialkyl-6-halo-chromans or thiochromans useful as pharmaceutical intermediates
EP0557722A3 (en) Process for producing 2,6-dimethylnaphthalene
AU6045394A (en) Process for producing intermediate for 13,14-didehydroprostaglandin e
HUT62255A (en) Process for producing radioprotective polyamine phenols
HU911705D0 (en) Process for producing 2,3-dichlorine-6-nitro-benzonitryl
GB2275268B (en) Improved process for the preparation of 4,4-diaryl-3,1-benzoxazines
HU9201152D0 (en) Method for producing 2,6-dialkyl-n-(alkoxi-methyl)-chloro-acetanilide

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees